Central nervous system-directed effects of FTY720 [old]

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Central nervous system-directed effects of FTY720 [old]

Postby CureOrBust » Fri Dec 18, 2009 3:25 am

Its getting old now (June 2008), but I had heard that FTY720 had some positive effects on the CNS, above the immune effects. This is the first article I have seen (abstract only) that goes partially to explain this rumour.

Central nervous system-directed effects of FTY720 (fingolimod)
Veronique E. Mirona, Anna Schubartb, Jack P. Antela
Received 10 April 2008; accepted 27 June 2008.

Abstract
FTY720, also known as fingolimod, is an orally administered sphingosine-1-phosphate (S1P) analogue that is under investigation as a therapy for both relapsing–remitting (RR) and progressive forms of multiple sclerosis (MS). The demonstrated beneficial effect of FTY720 on disease activity in RR–MS patients and in the animal model experimental autoimmune encephalomyelitis (EAE) is largely attributed to effects on the systemic immune system. In addition, unlike other current systemic immuno-modulators used in MS, the lipophilic nature of FTY720 allows it to cross the blood-brain barrier (BBB). Since S1P receptors are expressed on all cell types, FTY720 has the potential to exert effects directly on the BBB and on resident cells of the CNS. The latter include cells implicated in regulating immune reactivity within the CNS (astrocytes, microglia), those that are targeted by the disease process (oligodendrocytes, neurons), and those involved in repair (oligodendrocyte progenitor cells). In vitro studies document the dose-dependent effects of FTY720 on neural cell survival, differentiation, and cytoskeletal dynamics. Animal model studies, specifically EAE, indicate an overall neuroprotective effect of FTY720 mediated at least in part by its actions within the CNS. Ongoing studies will need to define the direct and indirect (via immune-modulation) effects of FTY720 on the CNS across the broad clinical spectrum of MS.

http://www.jns-journal.com/article/S0022-510X%2808%2900320-1/abstract

The confusing thing with the above, is in the human trials they seem to go for lower and lower doses, yet in this abstract they talk of a dose dependent effect.
User avatar
CureOrBust
Family Elder
 
Posts: 2914
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Advertisement

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post
  • FTY720
    by bromley » Tue Jul 19, 2005 11:03 am
    1 Replies
    1499 Views
    Last post by carolew View the latest post
    Sun Aug 07, 2005 3:44 am
  • FTY720
    by bromley » Mon Jul 25, 2005 5:55 am
    1 Replies
    1518 Views
    Last post by carolew View the latest post
    Sun Aug 07, 2005 3:48 am
  • FTY720
    by bromley » Sat Oct 01, 2005 1:54 am
    1 Replies
    1598 Views
    Last post by carolew View the latest post
    Sat Oct 01, 2005 12:18 pm
  • FTY720
    by bromley » Thu Mar 16, 2006 10:29 am
    4 Replies
    1909 Views
    Last post by billf View the latest post
    Thu Mar 23, 2006 11:32 am
  • FTY720
    by bromley » Mon Apr 24, 2006 3:17 am
    1 Replies
    1579 Views
    Last post by lorienhome View the latest post
    Sun Jun 04, 2006 6:30 am

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service